Enterprise Value to FCFF (EV/FCFF)
Free Cash Flow to The Firm (FCFF)
Cytokinetics Inc., FCFF calculation
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Item | Description | The company |
|---|---|---|
| FCFF | Free cash flow to the firm is the cash flow available to the Cytokinetics Inc. suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. | Cytokinetics Inc. FCFF decreased from 2020 to 2021 and from 2021 to 2022. |
Interest Paid, Net of Tax
Cytokinetics Inc., interest paid, net of tax calculation
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
2 2022 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= 15,165 × 0.00% = 0
Enterprise Value to FCFF Ratio, Current
Cytokinetics Inc., current EV/FCFF calculation, comparison to benchmarks
| Selected Financial Data (US$ in thousands) | |
| Enterprise value (EV) | 13,914,826) |
| Free cash flow to the firm (FCFF) | (296,741) |
| Valuation Ratio | |
| EV/FCFF | — |
| Benchmarks | |
| EV/FCFF, Competitors1 | |
| AbbVie Inc. | 14.30 |
| Amgen Inc. | 22.15 |
| Bristol-Myers Squibb Co. | 10.51 |
| Danaher Corp. | 33.21 |
| Eli Lilly & Co. | 661.15 |
| Gilead Sciences Inc. | 15.72 |
| Johnson & Johnson | 18.87 |
| Merck & Co. Inc. | 29.32 |
| Moderna Inc. | — |
| Pfizer Inc. | 30.11 |
| Regeneron Pharmaceuticals Inc. | 18.65 |
| Thermo Fisher Scientific Inc. | 26.75 |
| EV/FCFF, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 19.06 |
| EV/FCFF, Industry | |
| Health Care | 18.99 |
Based on: 10-K (reporting date: 2022-12-31).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Cytokinetics Inc., historical EV/FCFF calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Enterprise value (EV)1 | 3,931,450) | 2,644,163) | 1,003,554) | 787,578) | 173,561) | |
| Free cash flow to the firm (FCFF)2 | (296,741) | (183,513) | 7,511) | (89,467) | (99,213) | |
| Valuation Ratio | ||||||
| EV/FCFF3 | — | — | 133.61 | — | — | |
| Benchmarks | ||||||
| EV/FCFF, Competitors4 | ||||||
| AbbVie Inc. | 12.15 | 13.18 | 13.95 | 11.60 | — | |
| Amgen Inc. | 16.01 | 15.82 | 14.51 | 16.05 | — | |
| Bristol-Myers Squibb Co. | 13.87 | 10.52 | 11.63 | 23.39 | — | |
| Danaher Corp. | 25.74 | 28.25 | 30.66 | 37.11 | — | |
| Eli Lilly & Co. | 59.14 | 38.37 | 39.01 | 36.26 | — | |
| Gilead Sciences Inc. | 13.58 | 8.42 | 13.60 | 9.78 | — | |
| Johnson & Johnson | 23.80 | 21.25 | 20.75 | 19.31 | — | |
| Merck & Co. Inc. | 19.09 | 23.27 | 34.12 | 20.46 | — | |
| Moderna Inc. | 11.76 | 3.86 | 29.20 | — | — | |
| Pfizer Inc. | 9.15 | 8.40 | 21.74 | 19.44 | — | |
| Regeneron Pharmaceuticals Inc. | 17.96 | 9.81 | 25.74 | 19.54 | — | |
| Thermo Fisher Scientific Inc. | 31.61 | 33.14 | 26.14 | 28.88 | — | |
| EV/FCFF, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 17.82 | 15.03 | 20.02 | 19.33 | — | |
| EV/FCFF, Industry | ||||||
| Health Care | 17.63 | 16.41 | 17.93 | 18.26 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
3 2022 Calculation
EV/FCFF = EV ÷ FCFF
= 3,931,450 ÷ -296,741 = —
4 Click competitor name to see calculations.